US$2.61 billion in underlying profit (NPATA) attributable to CSL Limited Shareholders US$2.36 dividend per share for 2023 CSL Limited Annual Report 2022/23 2 1 Chair and CEO message Chair Message Dear Fellow Shareholders, I am pleased to share our results and operating review for the 2022/23 financial year. In the following pages you will see that CSL has once again performed strongly, with many operational highlights around the world. A Purpose-Driven Company To begin, I’d like to share my view on why our organisation exists. Your Board is grateful to have many long-term shareholders who have followed our story for decades. Our businesses, and certainly the science that underpins them, can be quite complex. Our purpose though is simple. The people and science of CSL save lives. We develop and deliver innovative medicines that help people with serious and life-threatening conditions live full lives, and protect the health of communities around the world. The great thing about our company is that in fulfilling this purpose, we create value for a variety of stakeholders. First and above all else, our most important task is to contribute to a healthier and more productive society. We do this by saving lives and protecting public health. Our second aim is financial growth – delivering consistent, profitable growth for our investors. It is our sustainable, financial growth that provides the fuel for more innovation and research. If done successfully, it is a great continuous loop: quality research leads to more research, which has the potential to create innovate therapies that benefits society. CSL has been able to demonstrate this over many years. Our third objective is about creating social and economic opportunities and enabling people to benefit as we grow as an organisation, be it employees, suppliers, plasma donors or research partners. Being able to create value in these ways is a great privilege, but also a responsibility. Good governance is an essential part of this responsibility. Leadership Transition The role of the Board is to guide our company in navigating the complexities of the world to create value over the long run. One aspect of this is talent: monitoring the composition of the Board and management teams so that we have the right skills to lead our company. During the year, Paul Perreault retired from his role of Chief Executive Officer (CEO) and Managing Director. The Board and I wish to acknowledge the remarkable leadership of Paul as CEO for 10 years. With Paul at the helm, CSL delivered sustainable growth and innovation with a patient-focused culture. Following a thorough process conducted by the Board, Dr Paul McKenzie was appointed as CEO and Managing Director of CSL from 6 March 2023. Dr McKenzie’s detailed work history can be found later in this report; he brings more than 30 years of leadership experience in the global biotechnology industry to CSL. He is a patient-focused leader with a demonstrated track record of leading complex organisations and delivering outstanding business results. This includes his time at CSL as the Chief Operating Officer, where he has been accountable for optimising CSL’s operations as well as growing the CSL Seqirus, CSL Behring and CSL Vifor businesses.
RkJQdWJsaXNoZXIy MjE2NDg3